Eupraxia Pharmaceuticals (EPRX) Q3 2026 earnings summary

Executive summary

• Reached target enrollment of 120 patients in the blinded, placebo-controlled Phase 2b RESOLVE trial of EP-104GI for EoE; interim analysis expected in December 2026.

• Open-label RESOLVE data showed 64% of patients remaining in clinical remission over 52 weeks, alongside clinically meaningful histologic improvements.

Financial highlights

• Q3 2026 net loss was $15.2M vs. $6.4M in Q3 2025; higher R&D from doubling Phase 2b trial size and higher G&A were partly offset by increased other income.

Outlook and guidance

• Interim Phase 2b RESOLVE data expected in December 2026; additional open-label Phase 1b/2a data planned in the coming months.

• Existing cash reserves are expected to fund operations into H2 2028.